Publications by authors named "Ravindra D R"

The high prevalence of oral potentially-malignant disorders exhibits diverse severity and risk of malignant transformation, which mandates a Point-of-Care diagnostic tool. Low patient compliance for biopsies underscores the need for minimally-invasive diagnosis. Oral cytology, an apt method, is not clinically applicable due to a lack of definitive diagnostic criteria and subjective interpretation.

View Article and Find Full Text PDF

Effective chemoprevention is critical for improving outcomes of oral cancer. As single agents, curcumin and metformin are reported to exhibit chemopreventive properties, in vitro as well as in patients with oral cancer. In this study, the chemopreventive efficacy of this drug combination was tested in a 4-nitro quinoline-1-oxide (4NQO) induced mice oral carcinogenesis model.

View Article and Find Full Text PDF

Chemoresistance leading to disease relapse is one of the major challenges to improve outcome in head and neck cancers. Cancer Stem Cells (CSCs) are increasingly being implicated in chemotherapy resistance, this study investigates the correlation between CSC behavior and acquired drug resistance in in vitro cell line models. Cell lines resistant to Cisplatin (Cal-27 CisR, Hep-2 CisR) and 5FU (Cal-27 5FUR) with high Resistance Indices (RI) were generated (RI ≥ 3) by short-term treatment of head and neck squamous cell carcinoma (HNSCC) cell lines with chemotherapeutic drugs (Cisplatin, Docetaxel, 5FU), using a dose-incremental strategy.

View Article and Find Full Text PDF
Article Synopsis
  • This study aimed to identify clinically relevant biomarkers for head and neck squamous cell carcinoma (HNSCC) by analyzing data from 20 public microarray series, focusing on gene expression differences between normal and tumor samples.
  • A total of 181 differentially expressed genes were identified, with significant interactions among many of them, and a gene panel (ECT2, ANO1, TP63, FADD, EXT1, NCBP2) was linked to alterations in about 30% of the tested tumor samples.
  • Validation in patient groups showed specific genes like ANO1 and FADD could predict recurrence and treatment response, indicating their potential as biomarkers for monitoring disease outcomes in HNSCC patients.
View Article and Find Full Text PDF